Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trilaciclib and Lurbinectedin in Small Cell Lung Cancer
NCT05578326Phase 2Recruiting
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Start
- Oct 2022
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of trilaciclib in small cell lung cancer (SCLC), sponsored by UNC Lineberger Comprehensive Cancer Center. Started Oct 2022; status: recruiting.
02
Drugs
trilaciclib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT05578326.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05578326.